Table 2.

Univariate outcomes

OutcomesHaploidentical donor (n = 132)MSD (n = 525)MUD TCD+ (n = 403)MUD TCD− (n = 378)
EvalProb (95% CI), %EvalProb (95% CI), %EvalProb (95% CI), %EvalProb (95% CI), %P
Neutrophil recovery126475383336.004
 28 d90 (84-94)97 (95-98)*95 (93-97)96 (93-98).10
 100 d99 (97-100)99 (98-100)98 (97-99)99 (98-100).79
Platelet recovery82342276238<.001
 28 d61 (50-71)92 (89-95)*89 (85-92)*89 (84-92)*<.001
 100 d91 (84-96)99 (97-100)*96 (93-98)98 (96-99).01
Acute GVHD 2-4123490377359.001
 180 d34 (26-43)32 (28-36)32 (28-38)42 (37-47).01
Acute GVHD 3-4123456377359<.001
 180 d7 (3-12)11 (9-14)13 (10-16)19 (15-23)*<.001
Chronic GVHD124522403335<.001
 1 y15 (9-21)41 (37-46)*23 (19-28)48 (42-53)*<.001
 2 y18 (12-26)48 (43-52)*27 (23-32)57 (52-63)*<.001
NRM132525403378.001
 1 y16 (10-23)13 (10-16)21 (17-26)20 (16-24).007
 3 y22 (15-30)17 (13-20)26 (21-31)30 (25-35)<.001
Relapse/progression132525403378<.001
 1 y34 (26-43)39 (34-43)33 (28-38)28 (23-33).01
 3 y41 (32-49)47 (42-51)38 (33-43)34 (29-39).001
PFS132525403378.72
 1 y50 (41-58)48 (44-53)%46 (40-51)52 (47-57).32
 3 y38 (29-47)37 (32-41)36 (31-41)37 (31-42).99
OS132525403378.36
 1 y66 (58-74)65 (61-69)56 (51-61)63 (58-68).03
 3 y46 (37-55)50 (45-55)43 (38-49)46 (41-52).32
  • Eval, number of evaluable patients; Prob, probability; TCD+, TCD with alemtuzumab or anti–thymocyte globulin; TCD−, TCD without alemtuzumab or anti–thymocyte globulin.

  • * Significant pairwise comparisons in reference to the haploidentical donor group.